ORIGINAL ARTICLE

Immune status, antibiotic medication and pH are associated with changes in the stomach fluid microbiota

Erik C von Rosenvinge^{1,2}, Yang Song³, James R White³, Cynthia Maddox³, Thomas Blanchard⁴ and W Florian Fricke^{3,5}

¹Division of Gastroenterology and Hepatology, University of Maryland School of Medicine, Baltimore, MD, USA; ²VA Maryland Health Care System, Department of Veterans Affairs, Baltimore, MD, USA; ³Institute for Genome Sciences, University of Maryland School of Medicine, Baltimore, MD, USA; ⁴Division of Gastroenterology, Department of Pediatrics, University of Maryland School of Medicine, Baltimore, MD, USA and ⁵Department of Microbiology and Immunology, University of Maryland School of Medicine, Baltimore, MD, USA

The stomach acts as a barrier to ingested microbes, thereby influencing the microbial ecology of the entire gastrointestinal (GI) tract. The stomach microbiota and the role of human host and environmental factors, such as health status or medications, in shaping its composition remain largely unknown. We sought to characterize the bacterial and fungal microbiota in the stomach fluid in order to gain insights into the role of the stomach in GI homeostasis. Gastric fluid was collected from 25 patients undergoing clinically indicated upper endoscopy. DNA isolates were used for PCR amplification of bacterial 16S ribosomal RNA (rRNA) genes and fungal internal transcribed spacers (ITS). RNA isolates were used for 16S rRNA cDNA generation and subsequent PCR amplification. While all stomach fluid samples are dominated by the phyla Firmicutes, Bacteroidetes, Actinobacteria, Proteobacteria and Fusobacteria (>99% of sequence reads), the transcriptionally active microbiota shows significant reduction in Actinobacteria (34%) and increase in *Campylobacter* (444%) ($P<0.003$), specifically the oral commensal and suspected intestinal pathogen *Campylobacter concisus*. Bacterial but not fungal diversity is reduced by antibiotic treatment (28%; $P<0.02$), immunosuppression in transplant recipients and HIV/AIDS patients (42%; $P<0.001$) and gastric fluid pH > 4 (70%; $P<0.05$). Immunosuppression correlates with decreased abundance of *Prevotella* (24%), *Fusobacterium* (2%) and *Leptotrichia* (6%) and increased abundance of *Lactobacillus* (3844%) ($P<0.003$). We have generated the first in-depth characterization of the human gastric fluid microbiota, using bacterial 16S rRNA gene and transcript, and fungal ITS amplicon sequencing and provide evidence for a significant impact of the host immune status on its composition with likely consequences for human health.

The ISME Journal (2013) 7, 1354–1366; doi:10.1038/ismej.2013.33; published online 7 March 2013

Subject Category: Microbe-microbe and microbe-host interactions

Keywords: stomach fluid; microbiome; ITS; 16S rRNA; immunosuppression; *Helicobacter pylori*

Introduction

The stomach plays a crucial role in the maintenance of gastrointestinal (GI) health, serving as a barrier against ingested infectious disease agents of the lower GI tract (Martinsen *et al.*, 2005). In healthy human subjects, inactivation of ingested pathogens is mediated by gastric fluid containing a combination of hydrochloric acid and proteolytic enzymes

(Tennant *et al.*, 2008). Correspondingly, impaired gastric acid secretion is associated with an increased risk of infection (Howden and Hunt, 1987). Hypochlorhydria can result from atrophic gastritis, gastric surgery or drugs that inhibit acid secretion (Martinsen *et al.*, 2005). The gastric environment is also subject to active control by innate and adaptive immune responses, as has been demonstrated by a large body of literature on *Helicobacter pylori* infection (Vorobjova *et al.*, 2008). A protective function against pathogen infection has also been attributed to the commensal microbiota, for example, by providing direct protection against colonization (Croswell *et al.*, 2009) or by mediating clearance (Endt *et al.*, 2010) of invading pathogens such as

Correspondence: WF Fricke, Institute for Genome Sciences, University of Maryland School of Medicine, 801 West Baltimore Street, Biopark II, Room 643, Baltimore, MD 21201, USA.

E-mail: wffricke@som.umaryland.edu

Received 25 August 2012; revised 18 January 2013; accepted 1 February 2013; published online 7 March 2013

Salmonella enterica. Whether the stomach microbiota performs similar tasks is unknown, as the microbial communities of the stomach have not been studied in detail. Moreover, it has not been shown if the gastric fluid supports an intrinsic microbiota different from that of adjacent locations of the GI tract, which could play a role for the stomach barrier function. Previous work has primarily focused on the microbiota of gastric mucosal biopsies in the context of *H. pylori* infection and applied only DNA-based methodologies that are unable to distinguish between transcriptionally active and inactive or dead bacteria (Bik *et al.*, 2006; Dicksved *et al.*, 2009; Maldonado-Contreras *et al.*, 2010). The specific aim of this study was therefore to characterize the microbiota of gastric fluid, in order to test the hypothesis that complex, transcriptionally active microbial communities exist in this environment, to provide insights into the colonization resistance of the stomach and reveal which organisms are likely to enter the intestine and thus influence the human host and microbiota in the lower GI tract. Expanding the donor population beyond *H. pylori*-infected subjects allowed for the evaluation of the influence of multiple external or environmental factors on the microbiota.

Towards this end, we address here the function of the stomach environment for GI health by determining the microbiota composition of gastric fluid in relation to various human host parameters, including immune status, gastric fluid pH, use of proton pump inhibitors (PPIs) and antibiotic medications. Through deep-sequencing of bacterial 16S ribosomal RNA (rRNA) genes and their transcripts as well as fungal internal transcribed spacers (ITS), we identify a diverse and transcriptionally active microbiota in stomach fluid that is critically shaped by the human host immune status, with potential implications for GI and overall human health and disease.

Materials and methods

Subject enrollment and sample collection

The study was approved by the Institutional Review Board of the University of Maryland Baltimore; all subjects provided their informed consent. Twenty-five adult patients undergoing clinically indicated upper endoscopy at the University of Maryland Medical Center were enrolled between December 2010 and June 2011. All samples were obtained in a hospital-based endoscopy laboratory, which operates between the hours of 0800 and 1700 hours. All patients were required to fast for a minimum of 8 h before the procedure. Demographics, clinical features and endoscopic indications and findings were recorded (Table 1). During the endoscopy, suction was not used until the endoscope entered the stomach to avoid contamination from other body sites. Gastric fluid was aspirated and collected in a sterile container. Samples were immediately put on

ice and within 2 h aliquoted (0.5 ml), combined with RNAlater (0.5 ml; Qiagen, Germantown, MD, USA) and frozen together with remaining raw samples at -80°C until further processing. Sample pH was determined using pH strips (Sigma-Aldrich, St Louis, MO, USA).

Nucleic acid isolation

DNA and RNA were isolated separately, using single aliquots per isolation. Samples were centrifuged at 5000 g for 8 min and the supernatant discarded. For DNA extraction, the cell pellets were re-suspended in 0.6 ml of $1\times$ phosphate-buffered saline and processed as described previously (Ravel *et al.*, 2011). Cell lysis was initiated with two enzymatic incubations, first using 5 μl of lysozyme (10 mg ml^{-1} ; Amresco, Solon, OH, USA), 13 μl of mutanolysin ($11.7\text{ U } \mu\text{l}^{-1}$; Sigma-Aldrich) and 3 μl of lysostaphin ($4.5\text{ U } \mu\text{l}^{-1}$; Sigma-Aldrich) for an incubation of 30 min at 37°C and, second, using 10 μl Proteinase K (20 mg ml^{-1} ; Research Products International, Mt Prospect, IL, USA), 50 μl 10% SDS and 2 μl RNase (10 mg ml^{-1}) for an incubation of 45 min at 56°C . After the enzyme treatments, cells were disrupted by bead beating in tubes with Lysing Matrix B (0.1 mm silica spheres, MP Biomedicals, Solon, OH, USA), at 6 ms^{-1} for 40 s at room temperature in a FastPrep-24 (MP Biomedicals). The resulting crude lysate was processed using the ZR Fecal DNA mini-prep kit (Zymo, Irvine, CA, USA) according to the manufacturer's recommendation. The samples were eluted with 100 μl of ultra pure water into separate tubes. DNA concentrations in the samples were measured using the Quant-iT PicoGreen dsDNA assay kit (Molecular Probes, Invitrogen, Carlsbad, CA, USA).

RNA isolation was performed by re-suspending pelleted cells in 1 ml TRIzol reagent (Ambion, Austin, TX, USA) and disrupting cells by bead beating as described above. The lysate was processed following the manufacturer's recommendations (Ambion) for RNA extraction with the following changes: in the phase separation step 300 μl of chloroform was added; the RNA precipitation step included 10 μg of added RNase-free glycogen (Fermentas, Waltham, MA, USA); 80% ethanol was used in RNA wash step. The RNA pellet was re-suspended in 41 μl of diethylpyrocarbonate-treated water (Ambion) without heated incubation. After pellet dissolution RNA samples were treated with 4 U DNaseI (Fermentas) and incubated for 1 h at 37°C . DNaseI was deactivated by the addition of 3 μl 0.5 mM EDTA and incubation at 65°C for 10 min.

Amplification and sequencing

Hypervariable regions V1–V2 of the bacterial 16S rRNA gene were amplified with primers 27F and 338R as described previously (Ravel *et al.*, 2011). Fungal ITS1 regions were amplified with primers

ITS1F and ITS2 (Ghannoum *et al.*, 2010). Additional primer sets were evaluated, including EF4/Fung5 (Smit *et al.*, 1999) and nu-SSU-0817-5/nu-SSU-1196-3 (Borneman and Hartin, 2000), which generated less consistent results than ITS1F and ITS2. Primers are shown in Supplementary Table 1.

DNA amplification of 16S rRNA genes was performed using AccuPrime Taq DNA polymerase High Fidelity (Invitrogen) and 50 ng of template DNA in a total reaction volume of 25 µl, following the AccuPrime product protocol. Reactions were run in a PTC-100 thermal controller (MJ Research, Waltham, MA, USA) using the following protocol: 3 min of denaturation at 94 °C, followed by 30 cycles of 30 s at 94 °C (denaturation), 30 s at 52 °C (annealing) and 45 s at 68 °C (elongation), with a final extension at 68 °C for 5 min. ITS amplicons were amplified as follows: 2 min of denaturation at 94 °C, followed by 35 cycles of 30 s at 94 °C (denaturing), 30 s at 50 °C (annealing) and 1 min at 68 °C (elongation), with a final extension at 68 °C for 5 min.

A two-step protocol was used to amplify 16S rRNA transcripts from RNA. All attempts to amplify ITS1 transcripts from total RNA isolates remained unsuccessful. The Phusion RT-PCR kit (Finnzymes, Waltham, MA, USA) was used to synthesize cDNA in a 20-µl volume with 250 ng RNA per reaction and the 338R primer (or ITS2) following the Phusion RT protocol. PCR amplification of the cDNA was set up as described above, using 2 µl of the cDNA template DNA and AccuPrime Buffer II as recommended by the manufacturer (Life Technologies, Carlsbad, CA, USA).

Negative controls were included for each amplification (PCR and RT-PCR) and barcoded primer pair, including amplification without template DNA and direct PCR amplification from RNA isolates. The presence of amplicons was confirmed by gel electrophoresis on a 2% agarose gel and staining with ethidium bromide. PCR and RT-PCR products were quantified using Quant-iT PicoGreen dsDNA assay. Equimolar amounts (50 ng) of the PCR amplicons were mixed in a single tube. Amplification primers and reaction buffer were removed using the AMPure Kit (Beckman Coulter, Brea, CA, USA) and purified amplicon mixtures sequenced at the Institute for Genome Sciences, University of Maryland, using 454 primer A and protocols recommended by the manufacturer (Roche, Branford, CT, USA). The 22 16S rRNA gene and 22 16S rRNA transcript amplicons (454 GS FLX adaptors) were sequenced as part of the same pool, which also contained 34 unrelated samples, on a half plate of the 454 GS FLX Titanium sequencer (Roche). The nine ITS DNA-derived amplicons (454 GS XLR adaptors) were sequenced together with 16S rRNA amplicons from 82 unrelated samples on a half plate of the 454 GS FLX Titanium sequencer. Raw sequences were deposited in the Short Read Archive Database (<http://www.ncbi.nlm.nih.gov/sra>, project number PRJNA168662).

Sequence processing and analysis

16S rRNA sequence reads were processed with CloVR (Angiuoli *et al.*, 2011), using the automated CloVR-16S pipeline as described in the corresponding standard operating procedure (White *et al.*, 2011). Briefly, sequences were binned based on sample-specific barcodes, trimmed by removal of barcode and primer sequences and filtered for quality, using a minimum sequence length of 100 nucleotides, a maximum homopolymer stretch of eight base pairs, a minimum quality score of 25 and a maximum number of ambiguous base pairs of 0. Reads were clustered into operational taxonomic units (OTUs) using a similarity threshold of 95%. On average, 20.6% of 16S rRNA reads were removed as chimeras. OTUs were classified using the RDP Naive Bayesian Classifier (Wang *et al.*, 2007) with a score filtering threshold of 0.5. Rarefaction curves were calculated based on OTU counts using the rarefaction.single routine of the Mothur package (Schloss *et al.*, 2009). Hierarchical clustering was performed using R. Differentially abundant OTUs were determined with Metastats (White *et al.*, 2009).

ITS amplicon sequence data were processed using the automated CloVR-ITS pipeline (White *et al.*, 2013) (<http://www.nature.com/protocolexchange/protocols/2597>). Briefly, sequence were binned, trimmed and filtered with QIIME (Caporaso *et al.*, 2010) using similar criteria as applied for the 16S rRNA sequence analysis. Sequences were clustered at 99% similarity with UCLUST (Edgar, 2010), chimeric clusters removed with UCHIME (mean: 0.9% of ITS reads per sample) and non-chimeric clusters (OTUs) taxonomically assigned based on BLASTN searches against an ITS reference database (White *et al.*, 2013).

Significance of phylogenetic distances (weighted and unweighted UniFrac) between sample groups was calculated in R, using Wilcoxon signed-rank tests. For these calculations, phylogenetic distances between samples assigned to the same group were compared with those between samples from different groups. *P*-values were calculated using two-tailed tests with a 5% significance level. Figures were generated by plotting the average distance between samples within the indicated group subtracted from the average distance between samples from the two compared groups.

Phylogenetic trees were created with FastTree2 (Price *et al.*, 2010) using trimmed alignments generated with NAST (DeSantis *et al.*, 2006), in case of 16S rRNA reads or Muscle (Edgar, 2004), in case of ITS reads. See Supplementary Figure legends for more details.

Results

Characterization of the gastric fluid microbiota

Microbial communities were analyzed in gastric fluid samples from 25 patients undergoing clinically indicated upper endoscopy, using bacterial 16S rRNA gene and transcript and fungal ITS amplicon

Table 1 Overview of patient clinical data

#	Sex	Age (years)	Race	pH	ABx	PPI	IMM	<i>H. pyl.</i> ^a	Other pt. clin.	End. indication	End. findings
2	F	34	AA	7.5	—	—	—	—	A, alcoholic hepatitis	UGIB	EG, MWT
15	F	33	AA	7.0	BL	+	G/M/CI	—	D, renal transplant	Melena, anemia	Erosive gastritis, RE
16	M	45	AA	2.0	—	—	—	+	G	Refractory hiccups	HH
26	F	42	AA	6.0	—	—	HIV/AIDS	+	G	Diarrhea, wt loss	CE, irreg. duodenal mucosa
31	M	52	C	1.5	—	+	—	—	G	Abdominal pain	HH
33	F	71	C	1.0	—	+	—	—	D, G, hyperparathyroidism	Dysphagia	GU
34	F	72	AA	8.5	—	+	G/M	16S	G, renal transplant	Anemia	EG
38	M	70	C	3.5	—	+	—	—	A, D, G	BE	BE, EG
41	F	38	C	4.5	—	+	—	—	A, G	Screen for BE	GU, EG, no BE
42	M	53	AA	7.0	—	+	HIV/AIDS	<i>glmM</i>	HCV cirrhosis, T	Screen for EV	EG, no EV
44	M	28	AA	1.0	—	—	—	+	T	Abdominal pain	None
48	M	36	C	3.0	—	+	—	—	A, G	BE, diarrhea	BE
49	F	33	C	1.0	—	+	—	—	None	Abdominal pain	None
50	F	79	AA	1.0	—	—	—	—	D, G	BE	BE
52	F	56	AA	6.5	—	+	G	—	D, G, sarcoidosis	Nausea	EG
56	M	68	AA	6.0	—	+	—	—	G, CAD, CKD	Melena	HH, RE
64	M	42	AA	7.0	FQ	+	HIV/AIDS	—	G	Abdominal pain	EG
67	F	67	AA	6.5	—	+	G/M/CI	—	D, G, renal transplant	UGIB	EG
68	F	50	C	1.5	—	—	—	—	T	Abdominal pain	None
76	M	42	C	2.5	—	—	—	—	A, T	UGIB	GU, DU
77	M	36	C	4.5	—	—	—	—	None	Hematochezia	Duodenitis
84	M	65	C	5.5	ML	+	—	—	D, G	Screen for BE	EG, gastric polyps
94	M	81	AA	6.5	—	—	—	—	Pernicious anemia	Early satiety	Atrophic gastritis
96	F	37	AA	5.5	THF + ML	+	HIV/AIDS	—	G, gastroparesis, T	Diarrhea	Retained food
97	F	27	C	1.0	—	—	—	—	T	Abdominal pain	None

Abbreviations: A, >1 alcoholic beverage per day; AA, African American; ABx, antibiotics (within 3 months before sampling); BE, Barrett's esophagus; BL, β -lactam + BL inhibitor; C, Caucasian; CAD, coronary artery disease; CE, candidal esophagitis; CI, calcineurin inhibitor; CKD, chronic kidney disease; D, diabetes; DU, duodenal ulcer(s); EG, erythematous gastropathy; End., endoscopic; EV, esophageal varices; F, female; FQ, fluoroquinolone; G, gastroesophageal reflux disease; G, glucocorticoids; GU, gastric ulcer(s); HH, hiatal hernia; IMM, immunosuppression; M, male; M, mycophenolate; ML, macrolide; MWT, Mallory–Weiss tear; PPI, proton pump inhibitor (at least 20 mg once daily for >1 day); pt. clin., patient clinical background; RE, reflux esophagitis; T, active tobacco use; THF, Tetrahydrofolate synthesis pathway-affecting antibiotic; UGIB, upper gastrointestinal bleeding; #, patient ID.

^aIdentified by *H. pylori glmM*-specific PCR (*glmM*), by 16S rRNA gene amplicon sequencing (16S) or both (+).

sequencing (Table 1). Of the 25 patients, 15 were analyzed by high-coverage (HC) amplicon sequencing with between 4809 and 19 589 sequence reads per data set (Table 2). Additional data sets from these and the remaining patients comprised between 138 and 548 reads per sample. HC data and rarefied low-coverage (LC) data, generated from all data sets subsampled to 250 reads per sample were analyzed separately.

Sample pH values varied between 1.0 and 8.5 (mean: 4.3; Table 1). While, on average, pH values were higher in samples from PPI-treated (pH: 4.9) compared with all other patients (pH: 3.4), this correlation was not significant (*P*-value, Student's *t*-test: 0.13). All samples, irrespective of human host backgrounds, were found to harbor diverse microbial communities (Figure 1). For the 16S rRNA gene amplicon sequence data, HC samples contained between 26 and 358 OTUs (mean: 183) and LC samples between eight and 56 OTUs (mean: 36) per sample (see Supplementary Tables 2 and 3). On average, HC samples were dominated by members of

the phyla Firmicutes (51.3%), Bacteroidetes (26.4%) and Actinobacteria (10.7%) (Figure 2a). Other prominent phyla included Proteobacteria (6.9%) and Fusobacteria (4.3%). Five samples were found to contain *H. pylori*, testing positive by either *H. pylori*-specific *glmM* PCR assay (Lu *et al.*, 1999) or 16S rRNA gene amplicon sequencing (Table 1). Alignment of the 16S rRNA reads from the two HC samples identified one *H. pylori* genotype per patient. *H. pylori* was not a dominant species within the gastric fluid microbiota, accounting for <0.4% of all sequence reads in all five patient samples where it was present. Presence of *H. pylori* was not associated with significant differences in microbiota diversity (Figures 1a and b) or high or low sample pH (Table 1).

16S rRNA transcript analysis identifies transcriptionally active microbiota

To identify stomach microbiota components that maintain metabolic activity in the stomach

Table 2 Sequencing results

Subject	Groups	16S DNA ^a	HC (LC) OTUs ^a	16S RNA ^b	HC (LC) OTUs ^b	ITS DNA ^c	OTUs ^c
2	HC + LC	12 755	358 (53)	424	— (48)	—	—
15	HC + LC	11 714	92 (15)	—	—	18 264	71
16	LC	458	— (46)	336	— (63)	—	—
26	LC	189	— (51)	184	— (39)	—	—
31	LC	254	— (56)	—	—	—	—
33	HC + LC	9649	214 (44)	12 847	241 (30)	15 856	72
34	HC + LC	10 676	105 (17)	14 071	86 (13)	—	—
38	HC + LC	11 570	284 (42)	513	— (42)	19 589	81
41	LC	—	—	343	— (41)	—	—
42	LC	321	— (49)	—	—	—	—
44	HC + LC	10 786	282 (39)	14 445	276 (37)	19 397	57
48	LC	548	— (37)	283	— (61)	—	—
49	LC	—	—	264	— (42)	—	—
50	HC + LC	11 096	215 (32)	11 660	208 (33)	5766	32
52	HC + LC	9973	172 (38)	12 419	213 (35)	—	—
56	HC + LC	8599	183 (42)	301	— (34)	—	—
64	HC + LC	9547	26 (8)	283	— (13)	10 737	42
67	HC + LC	4809	95 (32)	239	— (31)	—	—
68	LC	138	— (26)	316	— (40)	—	—
76	HC + LC	5143	165 (48)	298	— (48)	—	—
77	HC + LC	10 392	239 (43)	430	— (47)	16 407	61
84	LC	286	— (18)	124	— (17)	—	—
94	LC	197	— (27)	—	—	—	—
96	HC + LC	8118	114 (25)	110	— (14)	11 422	19
97	HC + LC	10 577	204 (30)	271	— (39)	16 582	51

Abbreviations: HC, high-coverage; ITS, internal transcribed spacers; LC, low-coverage; OTU, operational taxonomic unit.

^a16S rRNA gene PCR amplicon sequence reads.

^b16S rRNA transcript RT-PCR amplicon sequence reads.

^cInternal Transcribed Spacer PCR amplicon sequence reads. Numbers refer to reads that passed binning by sample barcode, filtering for length, quality, ambiguous base pairs, homopolymers and chimeras as described in the Materials and methods section.

Figure 1 Microbiota rarefaction curves. (a) Bacterial microbiota comparison of HC and (b) LC immunocompromised (transplant recipients and HIV/AIDS patients) and other patient samples; (c) Fungal microbiota comparison of HC immunocompromised and other patient samples. Samples from antibiotic-treated patients are boxed. *H. pylori*-positive samples are marked with *. AB, antibiotic-treated patient; OTU, operational taxonomic unit (equivalent of taxonomic species in the sequence space); TR, transplant recipient.

environment, 16S rRNA transcript amplicon sequence data were generated and compared with those from the 16S rRNA gene amplicon sequence data. For the 16S rRNA transcript analysis, total RNA isolates were used as templates for cDNA amplification with a reverse transcriptase polymerase and the 338R primer. PCR products were amplified from the cDNA with the same primers

(27F and 338R) and sequence processing conditions as for the DNA-based 16S rRNA analysis. The rationale behind this approach is that 16S rRNA transcripts should be less stable under conditions detrimental for the bacterial host than 16S rRNA genes. Between 11 660 and 14 445 sequence reads were obtained from the 16S rRNA transcript analysis for five HC samples and between 110 and 513

Figure 2 Relative gastric fluid microbiota compositions at the phylum level. (a) Comparison of 15 HC 16S rRNA gene samples. (b) Comparison of 16S rRNA gene and transcript samples in five HC pairs. (c) Average compositions of 16S rRNA gene and transcript samples. Samples from antibiotic-treated patients are boxed. AVG, average; D, 16S rRNA gene amplicon data; HIV, HIV/AIDS patients; R, 16S rRNA transcript data; TR, transplant recipient.

Figure 3 Phylogenetic distances between HC sample groups, using unweighted (a) and weighted (b) UniFrac analysis. Plots show the average distance between samples within the indicated groups subtracted from the average distance between samples from the two compared groups. IMM, immunocompromised (transplant recipients and HIV/AIDS patients) versus other patient samples; ABx, antibiotic-treated versus other patient samples; pH, low pH (1.0–4.0) versus high pH (4.0–8.5) patient samples; pH, imm-ctr., same as pH but excluding IMM; PPI, PPI-treated patient samples; PPI, imm-ctr., same as PPI but excluding IMM; DNA-RNA, 16S rRNA gene versus transcript data.

sequence reads were obtained for 17 LC samples (Table 2).

Phylogenetic distance calculations using weighted but not unweighted UniFrac analysis showed significant differences between 16S rRNA gene and transcript data (see Supplementary

Tables 4 and 5 and Figure 3). In addition, consistent shifts in relative distributions of the main taxonomic phyla were apparent in the comparison of 16S rRNA transcript and gene-based amplicon sequence data (Figure 2b), including a decrease in Actinobacteria and Firmicutes and an increase in Bacteroidetes and Proteobacteria. Due to limited numbers of sample pairs, these observations could not be supported statistically based on HC sequence data. However, significant changes between DNA and RNA-based microbiota compositions confirming several of these observations were identified using the larger LC sample group (Figure 4a). Compared with the total microbiota, the transcript-based microbiota fraction shows a statistically significant ($P < 0.003$) reduction in the class Actinobacteriia (34%; phylum: Actinobacteria), and an increase in the genera *Campylobacter* (444%; phylum: Proteobacteria) and *Tannerella* (680%; phylum: Bacteroidetes). Of the *Campylobacter* reads, >90% were assigned to a single species, *Campylobacter concisus*, based on sequence alignments and phylogenetic tree predictions (see Supplementary Figure 1). *C. concisus* is a known oral commensal bacterium, which has also been isolated from human feces (Van Etterijck et al., 1996). Members of the class Actinobacteriia, which had a lower relative abundance in 16S rRNA transcripts compared with genes, included known inhabitants of the oral cavity, such as *Rothia dentocariosa* (Brown et al., 1969) (on average 64% of Actinobacteriia) and *Actinomyces odontolyticus* (Batty, 1958) (on average 17% of Actinobacteriia).

Figure 4 Microbiota components with significantly different relative abundance between groups. (a) LC samples: Comparison of 16S rRNA gene-based and rRNA transcript-based microbiota; (b) HC Samples: Comparison of immunocompromised (transplant recipients and HIV/AIDS patients) and other patient samples; (c) LC samples: Comparison of immunocompromised (transplant recipients and HIV/AIDS patients) and other patient samples; (d) LC samples: Comparison of antibiotic-treated and other patient samples; Significant differences were calculated on five taxonomic levels (phylum, class, order, family, genus) using Metastats (White *et al.*, 2009) with a *P*-value threshold of 0.003, based on the taxonomic assignments of all reads with the RDP Bayesian classifier (Wang *et al.*, 2007). Taxa with significantly greater relative abundance in the first compared with the second group of samples are shown in red, those with lower abundance in blue, and those without significant difference in black. Only taxonomic lineages that contain at least one component of significantly different relative abundance between the compared groups are shown.

In the two HC samples that contained *H. pylori* (#34, #44), the relative abundance of *H. pylori* was, on average, 19.9 times higher in 16S rRNA transcripts compared with genes.

Impact of host immune status and pH on gastric microbiota

The 15 gastric fluid samples from the HC sample group could be divided into two subsets, based on microbiota species richness (Figure 1a) and composition (Figure 5), which coincided best with differences in the human host immune status. The distinction of a sample subset from immunocompromised patients could be confirmed using phylogenetic distance (weighted and unweighted UniFrac analysis) calculations (Figures 3 and 6; Supplementary Tables 4 and 5). Two samples from this immunocompromised patient group originated from HIV/AIDS patients and three from kidney transplant recipients who were taking immunosuppressive medication at the time of sample collection (Table 1), including MMF (mycophenolate mofetil), which affects B and T lymphocyte proliferation (Villaruel *et al.*, 2009). Among these five immunocompromised patient samples, there was a significant overlap (three out of five samples) with patients who had taken antibiotics around the time of sample collection (Figure 1a). All immunocompromised patient samples had pH values > 5 (mean: 6.9). PPI usage, when controlled for immunosuppression did not show a comparable impact on microbiota richness (data not shown) or composition (Figures 3 and 5; Supplementary Tables 4 and 5). Significant differences in phylogenetic distance (weighted and

unweighted UniFrac) were also measured between samples with low pH (1.0–4.0) and high pH (4.0–8.5), even when controlled for immunosuppression (Figure 3; Supplementary Tables 4 and 5; Supplementary Figure 2).

On average, bacterial richness in the five immunocompromised samples from transplant recipients and HIV/AIDS patients was reduced (42%; *P* < 0.001) compared with all other HC samples, measured by comparing the mean counts of OTUs per 2500 sequence reads. Statistically significant changes (*P* < 0.003) in the microbiota composition between these two groups included, at the phylum level, increased abundances of Firmicutes (221%) and reduced abundances of Bacteroidetes (15%), and, at the genus level, increased *Lactobacillus* spp. (3084%) and reduced *Fusobacterium* spp. (1%) and *Prevotella* spp. (16%) (Figure 4b). The *Lactobacillus* populations from the immunocompromised patient samples showed heterogeneous compositions, including members from different taxonomic species, as predicted by 16S rRNA sequence alignments and phylogenetic tree predictions (see Supplementary Figure 3).

Although not significant, similar trends were identified when comparing the 23 LC 16S rRNA gene samples, that is, lower bacterial species richness (75%; *P* < 0.2) and different microbiota composition in immunocompromised patient samples (Figure 1b). In addition, similar microbiota changes were found associated with immunocompromised patient samples from the HC and LC sample groups (Figure 4c), including increased abundance of the phylum Firmicutes (193%) and reduced abundance of Fusobacteria (4%). Among

Figure 5 Hierarchical clustering of HC 16S rRNA gene and transcript samples based on microbiota compositions. (a) Phylum level; (b) Genus level. Colors (yellow to red) show relative abundance per sample. Branches of the tree showing sample similarities based on hierarchical clustering are colored for transplant recipients (red) and HIV/AIDS patients (purple). Rows are also clustered hierarchically based on similar relative abundance values across samples (dendrogram not shown). Patient sample metadata are shown using checkerboard plots based on the following color codes: Antibiotic treatment (black) or no treatment (white) within 3 months before sample collection; high pH 4.0–8.5 (black) or low pH 1.0–4.0 (white); PPI treatment (black) or no treatment (white) within 24 h of sample collection; *H. pylori* presence (black) or absence (white) based on 16S rRNA gene amplicon sequencing; male (black) or female (white) sex; ethnicity: African American (black) or Caucasian (white); RNA/DNA: 16S rRNA transcript (black) or 16S rRNA gene (white) data. For age, black, gray and white boxes refer to 27–38, 42–56 and 65–81 years, respectively. See Table 1 for additional details.

the LC samples, a stronger correlation between antibiotic treatment and reduced bacterial species richness (45%; $P < 0.001$) was apparent than among the HC samples. In contrast to the HC samples, where no significant microbiota changes were found to correlate with antibiotic medication, several taxonomic groups are reduced in the LC samples from antibiotic-treated patients (Figure 4d), including the genus *Prevotella* (17%; phylum: Bacteroidetes), the family *Fusobacteriaceae* (7%; phylum: Fusobacteria) and the order Clostridiales

(7%; phylum: Firmicutes). High pH was not associated with significant reductions in bacterial diversity (81%; $P < 0.2$) or changes in the microbiota composition, except for an increase in members of the family *Veillonellaceae* (201%; phylum: Firmicutes).

Identification of a fungal gastric fluid microbiota

To study fungal members of the gastric fluid microbiota, ITS of the rRNA gene cluster were amplified in

Figure 6 Unscaled principal coordinate analysis (PCoA) plots showing unweighted (**a, b**) and weighted (**c, d**) UniFrac analysis of HC (**a, c**) and LC (**b, d**) samples. Samples are color coded as follows: Transplant recipient (red), HIV/AIDS patient (purple) or other (green) samples. 16S rRNA transcript data are marked with an 'R' after the patient number and outlined in black. Antibiotically treated patient samples are boxed.

a subset of nine randomly chosen samples, sequenced and processed using a similar methodology as for the 16S rRNA-based microbiota analysis (White *et al.*, 2013) (see Supplementary Table 6). After sequence binning, trimming and filtering between 5766 and 19 589 reads were obtained per sample and assigned to taxonomic lineages (Table 2). Samples contained between 19 and 81 genus-level OTUs. On average, 77.5% of ITS reads could not be taxonomically assigned, even at the phylum level, most likely due to incomplete representation of human-associated fungi in available ITS reference sequence collections (White *et al.*, 2013). *Candida* was one of the only two genera found in all samples, the other being *Phialemonium*. The known pathogens *C. albicans*, *C. tropicalis* and *C. parapsilosis* were identified based on phylogenetic tree predictions using publicly available *Candida* reference sequences (see Supplementary Figure 4). A correlation between human host immune status and fungal microbiota richness and/or composition was not found (Figure 1c; Supplementary Table 6). However, one of the two HIV/AIDS patients (#96) who was treated prophylactically against *Pneumocystis pneumonia* (PCP) with the tetrahydrofolate synthesis inhibitor trimethoprim/sulfamethoxazole and also took the macrolide azithromycin showed markedly reduced fungal microbiota richness (Figure 1c).

Discussion

Our results reveal that human gastric fluid harbors a diverse microbiota dominated by Actinobacteria,

Bacteroidetes, Firmicutes, Fusobacteria and Proteobacteria, demonstrating a similar overall composition at the phylum level as previously found in other GI tract locations, including intraoral niches (Zaura *et al.*, 2009; Crielaard *et al.*, 2011), throat (Andersson *et al.*, 2008), distal esophagus (Pei *et al.*, 2004), stomach mucosa (Bik *et al.*, 2006; Andersson *et al.*, 2008) and feces (Costello *et al.*, 2009). Fungal members of the microbiota are also identified, including the known pathogen *C. albicans*. Contrary to previous reports that studied the stomach environment based on biopsy samples from the mucosa (Bik *et al.*, 2006; Andersson *et al.*, 2008), *H. pylori*, if present, is not a dominant species within the gastric fluid microbiota of patients with an indication for upper endoscopy, a finding consistent with the literature showing that *H. pylori* colonizes the mucous layer and adheres to gastric epithelial cells (Amieva and El-Omar, 2008).

Using a 16S rRNA transcript amplicon sequencing strategy, significant differences are identified between the total (DNA) and transcriptionally active (RNA) microbiota. A similar approach was first applied by Zoetendal *et al.* (1998) to study fecal microbiota compositions (Zoetendal *et al.*, 1998). Peris-Bondia *et al.* (2011) used flow cytometry to sort cells based on total RNA content before performing 16S rRNA amplicon pyrosequencing and reported decreases in Bacteroidetes and increases in specific families of the Clostridiales (Firmicutes) from fecal samples (Peris-Bondia *et al.*, 2011). Typical bacterial inhabitants of the oral cavity unlikely to be adapted to the stomach, including

R. dentocariosa (Brown *et al.*, 1969) and *A. odontolyticus* (Batty, 1958), are reduced in 16S rRNA transcript fractions of the stomach fluid samples, supporting the utility of this method for characterization of the metabolically active gastric fluid microbiota. This characterization could have important implications for intestinal health, as only microbes that survive passage through the stomach are able to enter the lower GI tract and play a role in intestinal host/microbe homeostasis. Stomach fluid is typically believed to represent a harsh environment for bacterial growth due to low-pH acidic conditions, although our data indicate large variations in actual stomach fluid pH values, and increases in gastric pH after meals have been reported (Gardner *et al.*, 2002). The identification of transcriptionally active *C. concisus*, a known oral commensal and intestinal pathogen with a suspected role in Crohn's disease (Man *et al.*, 2010; Hess *et al.*, 2012), represents an example of a microbial organism that could be important for intestinal disease but would not draw attention with traditional 16S rRNA gene amplicon sequencing-based techniques, due to the low relative abundance. It should be noted that *C. concisus* has been especially associated with intestinal pathogenicity in immunocompromised patients (Aabenhus *et al.*, 2002) and that, among the five HC patient samples, the relative increase in *C. concisus* concentrations in RNA versus DNA isolates was even more pronounced in the single immunocompromised patient (#34) compared with the four other samples (1254% and 630%, respectively). In addition, all immunocompromised patient samples showed pH values above 6.0. Whether immunosuppression influences the barrier function of the stomach for intestinal pathogens needs to be further addressed in future studies.

The human host is suspected to play a major role in shaping the gastric fluid microbiota, in terms of both diversity and composition. Our results suggest that immune status is the most important determinant of gastric fluid microbiota, although antibiotic medication, which is often required in immunocompromised patients, and high gastric fluid pH, which can be caused by *H. pylori* infection and PPI usage among other factors, also seem to affect the microbiota diversity and composition. This is surprising since, unlike the small and large intestine, the lamina propria of the gastric mucosa typically lacks organized and diffuse lymphoid tissue. Immunocompromised HIV/AIDS patients and transplant recipients show markedly reduced diversity as well as altered composition of their gastric fluid microbiota. The effect of immunosuppressive medication on the microbiota appears restricted to transplant recipients, all of which were taking MMF and glucocorticoids at the time of sample collection. In contrast, a sample from a patient with sarcoidosis (#52), treated at the time of enrollment with a low dose (5 mg prednisone

daily) of glucocorticoids alone, did not show characteristics similar to the HIV/AIDS patient and transplant recipient samples. MMF, an inhibitor of purine biosynthesis, affects T and B lymphocyte proliferation and is known to cause GI adverse side effects (Villarroel *et al.*, 2009). Glucocorticoids exert anti-inflammatory effects through multiple often immune cell-specific mechanisms, including suppression of pro-inflammatory T cells and stimulation of regulatory T cells (Zen *et al.*, 2011). Similarities between the histological effects of GI toxicity induced by MMF and acute GVHD (graft-versus-host-disease) affecting the GI tract as well as HIV/AIDS have been pointed out before (Papadimitriou *et al.*, 2003). While the disease state of HIV/AIDS patients was not recorded as part of this study, CD4+ T-cell depletion of GALT (gut-associated lymphoid tissue) is an early event in the pathogenesis of human HIV infection and restoration is delayed even after highly active antiretroviral therapy (Guadalupe *et al.*, 2003). GALT harbors the majority of T lymphocytes in the human body (Nannini and Okhuysen, 2002), further suggesting that the T-cell-mediated adaptive immune response could be responsible for the observed microbiota changes in transplant recipients and HIV/AIDS patients samples and could be important for host-controlled GI tract homeostasis.

Similarities in infectious and other complications, especially of the GI tract, between HIV/AIDS patients and transplant recipients have been previously described (Thom and Forrest, 2006). Our observations of the gastric fluid microbiota in this patient group provide the opportunity for identifying potential microbiota-associated causes of disease. For example, the observed increase in *Lactobacillus* spp. seen in immunocompromised patients could be responsible for an increased risk of *Lactobacillus* bacteremia, which is rare in immunocompetent patients but has been reported in HIV/AIDS patients (Horwitch *et al.*, 1995) and organ transplant recipients (Patel *et al.*, 1994). Furthermore, Jenq *et al.* (2012) recently described changes in the microbiota of human and mouse bone marrow transplant recipients similar to those reported here, namely reduced diversity and increases in *Lactobacillales* in feces (humans) and ileum and cecum (mouse) (Jenq *et al.*, 2012). In the mouse model, the authors could also demonstrate a protective effect of *Lactobacillus* species against GVHD, a common complication of bone marrow transplantation, highlighting the potential therapeutic implications of the observed microbiota changes for the development of future pro- or antibiotic treatments.

Prior work suggests that acid-suppressing medications increase the risk of enteric infections (Leonard *et al.*, 2007) and the prevalence of non-*H. pylori* bacteria in gastric fluid (Sanduleanu *et al.*, 2001). Surprisingly, while high gastric fluid pH was associated with significant microbiota changes, our study did not detect a statistically significant

correlation between acid-suppressing medications and high gastric fluid pH (P -value: 0.13) or a direct impact of these medications on microbiota richness or composition. Larger studies will be needed before any conclusions can be drawn.

The present work has limitations. First, while care was taken to avoid aspiration of oropharyngeal and esophageal secretions, samples could have been contaminated from these areas, as the endoscope passed from the mouth to the stomach. In addition, while endoscopes undergo high-level disinfection before every use, they are not sterile. Sample storage conditions (Lauber *et al.*, 2010; Wu *et al.*, 2010) and DNA extraction methods (Maukonen *et al.*, 2012), as well as 16S rRNA gene amplification primers (Wu *et al.*, 2010) and biases inherent in PCR amplification, have all been shown to influence the results of microbiota analyses. PCR replicates were not performed. Therefore, the true composition of the gastric fluid microbiota remains unknown and could be different from the one reported here. However, the main results presented in this study should not have been affected by potential biases, as they were based on the comparison of samples collected and processed under similar conditions. Similarly, while 16S rRNA transcript analysis suggests the presence of a metabolically active microbiota in the stomach fluid, it does not answer the question whether an intrinsic microbiota that is native to the gastric fluid environment exists, or whether extrinsic microbes were detected from other environments, which are merely adapted to persist in this environment.

In conclusion, this study provides the identification and first in-depth characterization of microbial communities from the gastric fluid environment of the stomach. With 16S rRNA transcript sequence analysis, a methodology is presented for identification of the transcriptionally active component of the total stomach fluid microbiota. The results presented here demonstrate the existence of a gastric fluid microbiota, which contains fungi and is significantly influenced by the immune status and antibiotic regimen of the human host. These findings imply an important function of these factors for human GI health and could lead to the development of new therapeutic strategies with potential to improve GI health that may be particularly relevant to immunocompromised patients.

Acknowledgements

Funding for this study was provided by the National Human Genome Research Institute (NHGRI) and the Institute of Diabetes, Digestive and Kidney Diseases (NIDDK) from the National Institutes of Health (NIH) (RC2 HG005597 and R01 DK046461).

References

Aabenhus R, Permin H, On SL, Andersen LP. (2002). Prevalence of *Campylobacter concisus* in diarrhoea of

- immunocompromised patients. *Scand J Infect Dis* **34**: 248–252.
- Amieva MR, El-Omar EM. (2008). Host-bacterial interactions in *Helicobacter pylori* infection. *Gastroenterology* **134**: 306–323.
- Andersson AF, Lindberg M, Jakobsson H, Backhed F, Nyren P, Engstrand L. (2008). Comparative analysis of human gut microbiota by barcoded pyrosequencing. *PLoS One* **3**: e2836.
- Angiuoli SV, Matalka M, Gussman A, Galens K, Vangala M, Riley DR *et al.* (2011). CloVR: a virtual machine for automated and portable sequence analysis from the desktop using cloud computing. *BMC Bioinformatics* **12**: 356.
- Batty I. (1958). *Actinomyces odontolyticus*, a new species of actinomycete regularly isolated from deep carious dentine. *J Pathol Bacteriol* **75**: 455–459.
- Bik EM, Eckburg PB, Gill SR, Nelson KE, Purdom EA, Francois F *et al.* (2006). Molecular analysis of the bacterial microbiota in the human stomach. *Proc Natl Acad Sci USA* **103**: 732–737.
- Borneman J, Hartin RJ. (2000). PCR primers that amplify fungal rRNA genes from environmental samples. *Appl Environ Microbiol* **66**: 4356–4360.
- Brown JM, Georg LK, Waters LC. (1969). Laboratory identification of *Rothia dentocariosa* and its occurrence in human clinical materials. *Appl Microbiol* **17**: 150–156.
- Caporaso JG, Kuczynski J, Stombaugh J, Bittinger K, Bushman FD, Costello EK *et al.* (2010). QIIME allows analysis of high-throughput community sequencing data. *Nat Methods* **7**: 335–336.
- Costello EK, Lauber CL, Hamady M, Fierer N, Gordon JL, Knight R. (2009). Bacterial community variation in human body habitats across space and time. *Science* **326**: 1694–1697.
- Crielaard W, Zaura E, Schuller AA, Huse SM, Montijn RC, Keijser BJ. (2011). Exploring the oral microbiota of children at various developmental stages of their dentition in the relation to their oral health. *BMC Med Genomics* **4**: 22.
- Crowell A, Amir E, Teggatz P, Barman M, Salzman NH. (2009). Prolonged impact of antibiotics on intestinal microbial ecology and susceptibility to enteric *Salmonella* infection. *Infect Immun* **77**: 2741–2753.
- DeSantis TZ Jr., Hugenholtz P, Keller K, Brodie EL, Larsen N, Piceno YM *et al.* (2006). NAST: a multiple sequence alignment server for comparative analysis of 16S rRNA genes. *Nucleic Acids Res* **34**: W394–W399.
- Dicksved J, Lindberg M, Rosenquist M, Enroth H, Jansson JK, Engstrand L. (2009). Molecular characterization of the stomach microbiota in patients with gastric cancer and in controls. *J Med Microbiol* **58**: 509–516.
- Edgar RC. (2004). MUSCLE: multiple sequence alignment with high accuracy and high throughput. *Nucleic Acids Res* **32**: 1792–1797.
- Edgar RC. (2010). Search and clustering orders of magnitude faster than BLAST. *Bioinformatics* **26**: 2460–2461.
- Endt K, Stecher B, Chaffron S, Slack E, Tchitchek N, Benecke A *et al.* (2010). The microbiota mediates pathogen clearance from the gut lumen after non-typoidal *Salmonella* diarrhea. *PLoS Pathog* **6**: e1001097.

- Gardner JD, Ciociola AA, Robinson M. (2002). Measurement of meal-stimulated gastric acid secretion by in vivo gastric autotitration. *J Appl Physiol* **92**: 427–434.
- Ghannoum MA, Jurevic RJ, Mukherjee PK, Cui F, Sikaroodi M, Naqvi A et al. (2010). Characterization of the oral fungal microbiome (mycobiome) in healthy individuals. *PLoS Pathog* **6**: e1000713.
- Guadalupe M, Reay E, Sankaran S, Prindiville T, Flamm J, McNeil A et al. (2003). Severe CD4+ T-cell depletion in gut lymphoid tissue during primary human immunodeficiency virus type 1 infection and substantial delay in restoration following highly active antiretroviral therapy. *J Virol* **77**: 11708–11717.
- Hess DL, Pettersson AM, Rijnsburger MC, Herbrink P, van den Berg HP, Ang CW. (2012). Gastro-enteritis caused by *Campylobacter concisus*: case report and short review of literature. *J Med Microbiol* **61**: (Pt 5) 746–749.
- Horwitch CA, Furseth HA, Larson AM, Jones TL, Olliffe JF, Spach DH. (1995). Lactobacilemia in three patients with AIDS. *Clin Infect Dis* **21**: 1460–1462.
- Howden CW, Hunt RH. (1987). Relationship between gastric secretion and infection. *Gut* **28**: 96–107.
- Jenq RR, Ubeda C, Taur Y, Menezes CC, Khanin R, Dudakov JA et al. (2012). Regulation of intestinal inflammation by microbiota following allogeneic bone marrow transplantation. *J Exp Med* **209**: 903–911.
- Lauber CL, Zhou N, Gordon JI, Knight R, Fierer N. (2010). Effect of storage conditions on the assessment of bacterial community structure in soil and human-associated samples. *FEMS Microbiol Lett* **307**: 80–86.
- Leonard J, Marshall JK, Moayyedi P. (2007). Systematic review of the risk of enteric infection in patients taking acid suppression. *Am J Gastroenterol* **102**: 2047–2056. quiz 2057.
- Lu JJ, Perng CL, Shyu RY, Chen CH, Lou Q, Chong SK et al. (1999). Comparison of five PCR methods for detection of *Helicobacter pylori* DNA in gastric tissues. *J Clin Microbiol* **37**: 772–774.
- Maldonado-Contreras A, Goldfarb KC, Godoy-Vitorino F, Karaoz U, Contreras M, Blaser MJ et al. (2011). Structure of the human gastric bacterial community in relation to *Helicobacter pylori* status. *ISME J* **5**: 574–579.
- Man SM, Zhang L, Day AS, Leach ST, Lemberg DA, Mitchell H. (2010). *Campylobacter concisus* and other *Campylobacter* species in children with newly diagnosed Crohn's disease. *Inflamm Bowel Dis* **16**: 1008–1016.
- Martinsen TC, Bergh K, Waldum HL. (2005). Gastric juice: a barrier against infectious diseases. *Basic Clin Pharmacol Toxicol* **96**: 94–102.
- Maukonen J, Simoes C, Saarela M. (2012). The currently used commercial DNA-extraction methods give different results of clostridial and actinobacterial populations derived from human fecal samples. *FEMS Microbiol Ecol* **79**: 697–708.
- Nannini EC, Okhuysen PC. (2002). HIV1 and the gut in the era of highly active antiretroviral therapy. *Curr Gastroenterol Rep* **4**: 392–398.
- Papadimitriou JC, Cangro CB, Lustberg A, Khaled A, Nogueira J, Wiland A et al. (2003). Histologic features of mycophenolate mofetil-related colitis: a graft-versus-host disease-like pattern. *Int J Surg Pathol* **11**: 295–302.
- Patel R, Cockerill FR, Porayko MK, Osmon DR, Ilstrup DM, Keating MR. (1994). Lactobacilemia in liver transplant patients. *Clin Infect Dis* **18**: 207–212.
- Pei Z, Bini EJ, Yang L, Zhou M, Francois F, Blaser MJ. (2004). Bacterial biota in the human distal esophagus. *Proc Natl Acad Sci USA* **101**: 4250–4255.
- Peris-Bondia F, Latorre A, Artacho A, Moya A, D'Auria G. (2011). The active human gut microbiota differs from the total microbiota. *PLoS One* **6**: e22448.
- Price MN, Dehal PS, Arkin AP. (2010). FastTree 2—approximately maximum-likelihood trees for large alignments. *PLoS One* **5**: e9490.
- Ravel J, Gajer P, Abdo Z, Schneider GM, Koenig SS, McCulle SL et al. (2011). Vaginal microbiome of reproductive-age women. *Proc Natl Acad Sci USA* **108**(Suppl 1): 4680–4687.
- Sanduleanu S, Jonkers D, De Bruine A, Hameeteman W, Stockbrugger RW. (2001). Non-*Helicobacter pylori* bacterial flora during acid-suppressive therapy: differential findings in gastric juice and gastric mucosa. *Aliment Pharmacol Ther* **15**: 379–388.
- Schloss PD, Westcott SL, Ryabin T, Hall JR, Hartmann M, Hollister EB et al. (2009). Introducing mothur: open-source, platform-independent, community-supported software for describing and comparing microbial communities. *Appl Environ Microbiol* **75**: 7537–7541.
- Smit E, Leeftang P, Glandorf B, van Elsas JD, Wernars K. (1999). Analysis of fungal diversity in the wheat rhizosphere by sequencing of cloned PCR-amplified genes encoding 18S rRNA and temperature gradient gel electrophoresis. *Appl Environ Microbiol* **65**: 2614–2621.
- Tennant SM, Hartland EL, Phumoonna T, Lyras D, Rood JJ, Robins-Browne RM et al. (2008). Influence of gastric acid on susceptibility to infection with ingested bacterial pathogens. *Infect Immun* **76**: 639–645.
- Thom K, Forrest G. (2006). Gastrointestinal infections in immunocompromised hosts. *Curr Opin Gastroenterol* **22**: 18–23.
- Van Etterijck R, Breynaert J, Revets H, Devreker T, Vandenplas Y, Vandamme P et al. (1996). Isolation of *Campylobacter concisus* from feces of children with and without diarrhea. *J Clin Microbiol* **34**: 2304–2306.
- Villarroel MC, Hidalgo M, Jimeno A. (2009). Mycophenolate mofetil: An update. *Drugs Today (Barc)* **45**: 521–532.
- Vorobjova T, Watanabe T, Chiba T. (2008). *Helicobacter pylori* immunology and vaccines. *Helicobacter* **13**(Suppl 1): 18–22.
- Wang Q, Garrity GM, Tiedje JM, Cole JR. (2007). Naive Bayesian classifier for rapid assignment of rRNA sequences into the new bacterial taxonomy. *Appl Environ Microbiol* **73**: 5261–5267.
- White JR, Arze C, Matalaka M, Team TC, White O, Angiuoli SV et al. (2011). CloVR-16S: Phylogenetic microbial community composition analysis based on 16S ribosomal RNA amplicon sequencing—standard operating procedure, version 1.1. *Nature Preced*; doi:10.1038/npre.2011.6287.2.
- White JR, Maddox C, White O, Angiuoli SV, Fricke WF. (2013). CloVR-ITS: automated internal transcribed spacer amplicon sequence analysis pipeline for the characterization of fungal microbiota. *Microbiome* **1**: 6.
- White JR, Nagarajan N, Pop M. (2009). Statistical methods for detecting differentially abundant features in clinical metagenomic samples. *PLoS Comput Biol* **5**: e1000352.

- Wu GD, Lewis JD, Hoffmann C, Chen YY, Knight R, Bittinger K *et al.* (2010). Sampling and pyrosequencing methods for characterizing bacterial communities in the human gut using 16S sequence tags. *BMC Microbiol* **10**: 206.
- Zaura E, Keijser BJ, Huse SM, Crielaard W. (2009). Defining the healthy 'core microbiome' of oral microbial communities. *BMC Microbiol* **9**: 259.
- Zen M, Canova M, Campana C, Bettio S, Nalotto L, Rampudda M *et al.* (2011). The kaleidoscope of glucocorticoid effects on immune system. *Autoimmun Rev* **10**: 305–310.
- Zoetendal EG, Akkermans AD, De Vos WM. (1998). Temperature gradient gel electrophoresis analysis of 16S rRNA from human fecal samples reveals stable and host-specific communities of active bacteria. *Appl Environ Microbiol* **64**: 3854–3859.

Supplementary Information accompanies this paper on The ISME Journal website (<http://www.nature.com/ismej>)